ulian Sterling brings a Ph.D.-level understanding to Healthcare and Life Sciences law. He represents biotech firms and pharmaceutical giants in high-stakes patent interference and Hatch-Waxman litigation. His dual expertise allows him to lead cross-functional teams of scientists and legal associates in defending multi-billion dollar drug portfolios.

Representative Matters:

• CRISPR Patent Interference: Lead counsel for a university-spinout biotech in a high-profile patent interference proceeding regarding gene-editing technology. Successfully established his client’s "prior conception" and secured the foundational patent rights.

• Biologics Litigation: Defended a pharmaceutical manufacturer in a patent infringement suit involving a biosimilar drug for oncology. Julian’s team identified critical prior art that forced the plaintiff to abandon its primary claims on the eve of trial.

• Diagnostic Platform Strategy: Designed a comprehensive IP strategy for a personalized medicine company using AI to detect early-stage cancers, navigating the complex "patent-eligible subject matter" hurdles in the wake of Myriad Genetics.